The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2021 | Latest developments in the treatment of EMD in myeloma
Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, outlines the latest thinking on the optimal treatment of extramedullary disease (EMD) in myeloma. Recent data from the Phase II HORIZON study of melflufen in combination with dexamethasone in patients with relapsed/refractory myeloma demonstrated promising efficacy of the combination in the EMD setting. CAR T-cell therapy is currently recommended as an effective option for the treatment of EMD. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
